Central sensitization is a condition of enhanced excitability of spinal cord neurons that contributes to the exaggerated
pain sensation associated with chronic tissue or nerve injury.
N-methyl-D-aspartate (
NMDA) receptors are thought to play a key role in central sensitization. We have tested this hypothesis by characterizing in vitro and in vivo a novel antagonist of the
NMDA receptor acting on its
glycine site,
GV196771A.
GV196771A exhibited an elevated affinity for the
NMDA glycine binding site in rat cerebral cortex membranes (pKi = 7.56). Moreover,
GV196771A competitively and potently antagonized the activation of
NMDA receptors produced by
glycine in the presence of
NMDA in primary cultures of cortical, spinal, and hippocampal neurons (pKB = 7.46, 8. 04, and 7.86, respectively). In isolated baby rat spinal cords, 10 microM
GV196771A depressed wind-up, an electrical correlate of central sensitization. The antihyperalgesic properties of
GV196771A were studied in a model of chronic constriction injury (CCI) of the rat sciatic nerve and in the mice
formalin test. In the CCI model
GV196771A (3 mg/kg twice a day p.o.), administered before and then for 10 days after nerve
ligature, blocked the development of
thermal hyperalgesia. Moreover,
GV196771A (1-10 mg/kg p.o.) reversed the
hyperalgesia when tested after the establishment of the CCI-induced
hyperalgesia. In the
formalin test
GV196771A (0.1-10 mg/kg p.o.) dose-dependently reduced the duration of the licking time of the late phase. These antihyperalgesic properties were not accompanied by development of tolerance. These observations strengthen the view that
NMDA receptors play a key role in the events underlying
plastic phenomena, including
hyperalgesia. Moreover, antagonists of the
NMDA glycine site receptor could represent a new analgesic class, effective in conditions not sensitive to classical
opioids.